Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation.
Hilger
R A
RA
Department of Internal Medicine (Cancer Research), University of Essen Medical School, West German Cancer Center, Essen, Germany. ralf.hilger@uni-essen.de
Baumgart
J
J
Scheulen
M E
ME
Trenschel
R
R
Strumberg
D
D
Seeber
S
S
Beelen
D W
DW
D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D002066:Busulfan / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use*; D006207:Half-Life; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008657:Metabolic Clearance Rate; D019653:Myeloablative Agonists / Q000627:therapeutic use; D014018:Tissue Distribution; D019172:Transplantation Conditioning
D018906:Antineoplastic Agents, Alkylating; D019653:Myeloablative Agonists; D003520:Cyclophosphamide; C018404:treosulfan; D002066:Busulfan